logo
EH_logo
Tissue factor has been a historically under-exploited central biological target and is a fundamental mediator of innate immune activity and coagulation. It is a driver of inflammation, chemotaxis, and hemostasis across a broad range of IMIDs, including ulcerative colitis, Crohn’s disease, lupus, and certain vasculitides

Endpoint Health Unveils Precision Immunology Program to Address Tissue Factor-Mediated Inflammation in Autoimmune Diseases

Endpoint Health, Inc., a Precision-First TM therapeutics company, today unveiled its newest precision immunology program targeting inflammation mediated by tissue factor (TF)-dependent intracellular signaling

By AP News
Published - Oct 04, 2022, 08:11 AM ET
Last Updated - Jul 15, 2024, 06:08 AM EDT

PALO ALTO, Calif.--(BUSINESS WIRE)--Oct 4, 2022--

Endpoint Health, Inc., a Precision-First TM therapeutics company, today unveiled its newest precision immunology program targeting inflammation mediated by tissue factor (TF)-dependent intracellular signaling. The company will leverage its precision AI platform to identify potential responders to the program’s lead asset, EP004, a first-in-class anti-TF monoclonal antibody (mAb), across multiple autoimmune indications. Developing this first-in-class therapy with an innovative precision AI platform across a wide range of indications could potentially transform the treatment paradigm for patients with immune-mediated inflammatory diseases (IMIDs). Rather than using traditional “one-size-fits-all” therapies, this novel precision medicine strategy could enable health care providers to design a treatment plan optimized for each patient’s unique biology.

Tissue factor has been a historically under-exploited central biological target and is a fundamental mediator of innate immune activity and coagulation. It is a driver of inflammation, chemotaxis, and hemostasis across a broad range of IMIDs, including ulcerative colitis, Crohn’s disease, lupus, and certain vasculitides. Tissue factor represents an attractive target for disease modifying therapies designed to decrease pro-inflammatory cytokines and chemokines. EP004 (formerly ICON-4) is a first-in-class anti-TF mAb that is uniquely designed to reduce inflammation by selectively inhibiting TF-dependent intracellular signaling, while avoiding interaction with hemostasis-related functions of the TF pathway. EP004 is currently completing IND-enabling studies, and the company expects an IND submission in 2023.

This newly unveiled precision immunology program was made possible by Endpoint Health’s recent acquisition of Iconic Therapeutics, a preclinical-stage biotech company developing selective therapies including ICON4 (now EP004) to address TF-mediated signaling.

Our Offices
  • 10kInfo, Inc.
    13555 SE 36th St
    Bellevue, WA 98006
  • 10kInfo Data Solutions, Pvt Ltd.
    Claywork Create
    11 km, Arakere Bannerghatta Rd, Omkar Nagar, Arekere,
    Bengaluru, Karnataka 560076
4.2 12182024